Readiness of High-Risk Populations in the HIV Network for Prevention Trials to Participated in HIV Vaccine Efficacy Trials in the United States

Laboratory of Epidemiology, The New York Blood Center, New York 10021, USA.
AIDS (Impact Factor: 5.55). 06/1998; 12(7):785-93. DOI: 10.1097/00002030-199807000-00015
Source: PubMed


To determine the willingness of populations at high risk of HIV-1 infection to participate in HIV vaccine efficacy trials, determine factors influencing decision-making, and evaluate knowledge levels of vaccine trial concepts.
Cross-sectional study.
HIV-1-negative homosexual men, male and female injecting drug users and non-injecting women at heterosexual risk were recruited in eight cities in the United States (n=4892).
A substantial proportion of the study population (77%) would definitely (27%) or probably (50%) be willing to participate in a randomized vaccine efficacy trial. Increased willingness was associated with high-risk behaviors, lower education level, being uninsured or covered by public insurance, and not having been in a previous vaccine preparedness study. Altruism and a desire for protection from the vaccine were major motivators for participation. Major concerns included positive HIV-1 antibody test due to vaccine, safety of the vaccine, and possible problems with insurance or foreign travel. Baseline knowledge of vaccine trial concepts was low.
It is likely that high-risk volunteers will be willing to enroll in HIV vaccine efficacy trials. A variety of participant and community educational strategies are needed to address participant concerns, and to ensure understanding of key concepts prior to giving consent for participation.

Download full-text


Available from: Kenneth Mayer,
  • Source
    • "identifier: NCT01436357 and NCT01296451) aims to elicit a Tcell response associated with spontaneous clearance and therefore viral persistence estimates (progression to chronic HCV infection ) are necessary for sample size projections for Phase III assessment. While HIV VPS have included PWID, this population has typically comprised only a minority of study participants [19] [20] [21]. As part of the first HCV VPS, this paper reports key outcomes impacting HCV vaccine trial feasibility in PWID based on a community-based prospective observational study of HCV antibody negative PWID – the Hepatitis C Incidence and Transmission Study-community (HITS-c). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Efficacy trials of preventive hepatitis C virus (HCV) vaccine candidates raise challenging scientific and ethical issues. Based on data from the first 3years of a community-based prospective observational study - the Hepatitis C Incidence and Transmission Study-community (HITS-c) - this paper examines the feasibility of conducting trials of candidate HCV vaccines with people who inject drugs (PWID) in Sydney, Australia. Of the 166 PWID confirmed HCV antibody negative and eligible for enrolment, 156 (94%) completed baseline procedures. Retention was high, with 89% of participants retained at 48weeks and 76% of participants completing at least 75% of study visits within 2weeks of schedule. The rate of primary HCV infection was 7.9/100py (95% CI 4.9, 12.7). Of the 17 incident cases, 16 completed at least one follow-up assessment and 12 (75%) had evidence of chronic viraemia with progression to chronic HCV infection estimated to be 6/100py. Power calculations suggest a chronic HCV infection rate of at least 12/100py (primary HCV infection rate 16/100py) will be required for stand-alone trials of highly efficacious candidates designed to prevent chronic infection. However, elevated primary HCV infection was observed among participants not receiving opioid substitution therapy who reported heroin as the main drug injected (26.9/100py, 95% CI 14.5, 50.0) and those who reported unstable housing (23.5/100py, 95% CI 7.6, 72.8), daily or more frequent injecting (22.7/100py, 95% CI 12.2, 42.2) and receptive syringe sharing (23.6/100py, 95% CI 9.8, 56.7) in the 6months prior to baseline. These data suggest that it is possible to recruit and retain at-risk PWID who adhere to study protocols and that modification of eligibility criteria may identify populations with sufficiently high HCV incidence. Results support the feasibility of large multi-centre HCV vaccine trials, including in the Australian setting.
    Vaccine 08/2014; 32(42). DOI:10.1016/j.vaccine.2014.07.091 · 3.62 Impact Factor
  • Source
    • "Protection against HCV infection through trial enrolment was identified as a motivator for participation by several participants. As observed in previous studies (Koblin et al., 1998; Meyers et al., 1995), this expectation is of concern, given that in any trial, half the participants will be randomised to placebo and, even among those who receive the vaccine, initial vaccine efficacy is expected to be low to moderate (Houghton and Abrignani, 2005). Several participants who held contingent WTP also expressed concerns about low vaccine efficacy suggesting that this issue warrants further investigation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A safe and efficacious vaccine may be the most efficient and cost-effective strategy for controlling the hepatitis C virus (HCV) epidemic among people who inject drugs (PWID) and several candidates are in development. However, little is known about the factors that influence willingness to participate (WTP) in candidate HCV vaccine trials among this group. HCV seronegative PWID recruited between 2008 and 2010 as part of a prospective observational cohort study in Sydney, Australia were asked whether they would be willing to participate in a future candidate hepatitis C vaccine trial and to provide reasons to explain their decision. Of 113 participants, 74% indicated WTP, 15% were unwilling to participate and 11% reported WTP that was contingent on vaccine characteristics and trial design issues. The most commonly reported motivator for hypothetical trial participation was altruism, followed by potential health benefits, financial remuneration, and knowledge gain. Barriers to hypothetical participation included fears about possible harms to health, such as concerns about vaccine safety, side effects, and acquiring HCV from the vaccine; other barriers included mistrust of biomedical research and time constraints. These results may be useful in designing strategies to enhance HCV vaccine trial recruitment and retention and have ethical implications for developing informed consent processes and standards of care.
    Drug and alcohol dependence 11/2011; 123(1-3):35-40. DOI:10.1016/j.drugalcdep.2011.10.009 · 3.42 Impact Factor
  • Source
    • "Motivators have included altruism, helping to end the HIV/ AIDS epidemic, and personal benefits such as HIV testing, HIV information, protection from HIV, medical care and financial compensation [3] [14] [15] [16] [17] [18] [19] [20] [21]. Deterrents included concerns about safety, side effects, contracting HIV from the vaccine, vaccine-induced seropositivity (VISP), trust, confidentiality, social stigma, discrimination, family member concerns, insurability, study design, and pragmatic obstacles to participating [4] [12] [14] [15] [17] [22] [23]. However in actual HIV vaccine trials, some sites recruiting diverse populations have reported lower rates of enrollment among women and minorities [3] [24], suggesting that factors influencing minority women's participation may be systematically different from those of other groups [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Efficacy studies of investigational HIV vaccines require enrollment of individuals at 'high risk' for HIV. This paper examines participation in HIV vaccine trials among women at 'high risk' for HIV acquisition. In-depth interviews were conducted with 17 African-American women who use crack cocaine and/or exchange sex for money/drugs to elicit attitudes toward medical research and motivators and deterrents to HIV vaccine trial participation. Interviews were digitally recorded and transcribed; data were coded and compiled into themes. Most women expressed favorable attitudes toward medical research in general. Motivators for trial participation included compensation; personal benefits including information, social services, and the possibility that the trial vaccine could prevent HIV; and altruism. Deterrents included: dislike of needles; distrust; concern about future consequences of participating. In addition, contingencies, care-giving responsibilities, and convenience issues constituted barriers which could impede participation. Respondents described varied, complex perspectives, and individual cases illustrate how these themes played out as women contemplated trial participation. Understanding factors which influence vaccine research participation among women at 'high risk' can aid sites to tailor recruitment procedures to local contexts. Concerns about future reactions can be addressed through sustained community education. Convenience barriers can be ameliorated by providing rides to study visits when necessary, and/or conducting study visits in accessible neighborhood locations. Women in this sample thought carefully about enrolling in HIV vaccine trials given the structural constraints within which they lived. Further research is needed regarding structural factors which influence personal agency and individuals' thinking about research participation.
    Vaccine 06/2011; 29(36):6130-5. DOI:10.1016/j.vaccine.2011.06.064 · 3.62 Impact Factor
Show more